Most Read Articles
Pearl Toh, 5 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 2 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
6 days ago

It appears that patients with rheumatoid arthritis (RA) are at an increased risk of obstructive sleep apnoea (OSA) secondary to both traditional and RA-related risk factors, a recent study has found.

Yesterday
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.

Tadalafil does not help lessen ambulatory ability decline in boys with DMD

12 Dec 2017

Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.

The study randomized 331 boys (mean age 9.6 years) with DMD to receive tadalafil 0.3 mg·kg−1·d−1, tadalafil 0.6 mg·kg−1·d−1 or placebo for 48 weeks. Efficacy was assessed using the 6-minute walk distance (6MWD). Secondary efficacy measures were North Star Ambulatory Assessment and timed function tests. Performance of Upper Limb (PUL) was examined as a prespecified exploratory outcome.

Tadalafil did not exert an effect on the primary outcome. The 6MWD after 48 weeks of treatment decreased by 51.0 m with placebo, 64.7 m with low-dose tadalafil (p=0.307 vs placebo) and 59.1 m with high-dose tadalafil (p=0.538 vs placebo). The drug had no effect on secondary outcomes.

In the group of patients aged >10 years, those treated with low-dose tadalafil showed smaller declines in total PUL score and shoulder subscore compared with those who received placebo.  

Drug-related adverse events were reported in 41.4 percent of patients in the placebo group, 50.0 percent in the low-dose tadalafil group and 59.8 percent in the high-dose tadalafil group.

Adverse events were consistent with the known safety profile of tadalafil and the DMD disease state, researchers noted. “Safety monitoring revealed the expected increase in penile erections with tadalafil without priapism.”

Additional research is warranted to determine whether ambulatory decline in DMD can be lessened by initiation of PDE5 inhibition before 7 years of age, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 2 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
6 days ago

It appears that patients with rheumatoid arthritis (RA) are at an increased risk of obstructive sleep apnoea (OSA) secondary to both traditional and RA-related risk factors, a recent study has found.

Yesterday
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.